First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study.

Front Immunol · 2026 · PMC13284605 · PMID 42338583

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

While the CASPIAN trial suggested a trend toward reduced risk of new CNS lesions with durvalumab, the benefit failed to reach statistical significance, and the reported median iPFS of 4.7 months was numerically inferior to our finding ( 15 ).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.